A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

被引：0

作者：

Terpos, Evangelos ^{[1
]}

Kastritis, Efstathios ^{[2
]}

Symeonidis, Argiris ^{[3
]}

Pouli, Anastasia ^{[4
]}

Delimpasi, Sosana ^{[5
]}

Katodritou, Eirini ^{[6
]}

Hatzimichael, Eleftheria ^{[7
]}

Ntanasis-Stathopoulos, Ioannis ^{[8
]}

Malandrakis, Panagiotis ^{[8
]}

Fotiou, Despina ^{[8
]}

Migkou, Magdalini ^{[8
]}

Theodorakakou, Foteini ^{[8
]}

Spiliopoulou, Vasiliki ^{[8
]}

Syrigou, Rodanthi ^{[8
]}

Eleutherakis-Papaiakovou, Evangelos ^{[2
]}

Manousou, Kyriaki ^{[9
]}

Gavriatopoulou, Maria

Dimopoulos, Meletios A. ^{[2
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Univ Patras, Sch Med, Hematol Div, Dept Internal Med, Patras, Greece

[4] St Savvas Oncol Hosp, Hematol Dept, Athens, Greece

[5] Gen Hosp Evangelismos, Athens, Greece

[6] Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece

[7] Univ Ioannina, Dept Hematol, Fac Med, Ioannina, Greece

[8] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[9] Hlth Data Specialists, Dublin, Ireland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[11] Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
Kumar, S. K.
Flinn, I.
Noga, S. J.
Hari, P.
Rifkin, R.
Callander, N.
Bhandari, M.
Wolf, J. L.
Gasparetto, C.
Krishnan, A.
Grosman, D.
Glass, J.
Sahovic, E. A.
Shi, H.
Webb, I. J.
Richardson, P. G.
Rajkumar, S. V.
LEUKEMIA, 2010, 24 (07) : 1350 - 1356
[12] Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
Facon, Thierry
Dimopoulos, Meletios Athanasios
Leleu, Xavier P.
Beksac, Meral
Pour, Ludek
Hajek, Roman
Liu, Zhuogang
Minarik, Jiri
Moreau, Philippe
Romejko-Jarosinska, Joanna
Spicka, Ivan
Vorobyev, Vladimir I.
Cavo, Michele
Goldschmidt, Hartmut
Martin, Thomas G.
Manier, Salomon
Bregeault, Marie-France
Mace, Sandrine
Berthou, Christelle
Orlowski, Robert Z.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[13] Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).
Ocio, Enrique M.
Rodriguez Otero, Paula
Bringhen, Sara
Oliva, Stefania
Nogai, Axel
Attal, Michel
Moreau, Philippe
Martinez-Lopez, Joaquin
Le Roux, Nadia
Mace, Sandrine
Rouchon, Marie-Claude
Wang, Qiuyan
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[14] Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)
Facon, Thierry
Dimopoulos, Meletios
Leleu, Xavier
Beksac, Meral
Pour, Ludek
Hajek, Roman
Liu, Zhuogang
Minarik, Jiri
Moreau, Philippe
Romejko-Jarosinska, Joanna
Spicka, Ivan
Vorobyev, Vladimir
Cavo, Michele
Goldschmidt, Hartmut
Martin, Thomas
Manier, Salomon
Bregeault, Marie-France
Mace, Sandrine
Berthou, Christelle
Orlowski, Robert
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S31 - S31
[15] Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
Leleu, Xavier P.
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Manier, Salomon
Perrot, Aurore
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Laribi, Kamel
Chretien, Marie-Lorraine
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[16] Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study
Askeland, Frida Bugge
Haukas, Einar
Slordahl, Tobias S.
Klostergaard, Anja
Alexandersen, Tatjana
Schjoll, Diana
Lysen, Anna
Hermansen, Emil
Schjesvold, Fredrik
BLOOD, 2023, 142
[17] Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Ocio, Enrique M.
Perrot, Aurore
Bories, Pierre
San-Miguel, Jesus F.
Blau, Igor W.
Karlin, Lionel
Martinez-Lopez, Joaquin
Wang, Song-Yau
Bringhen, Sara
Marcatti, Magda
Mateos, Maria-Victoria
Rodriguez-Otero, Paula
Oliva, Stefania
Nogai, Axel
Le Roux, Nadia
Dong, Liyan
Mace, Sandrine
Gassiot, Matthieu
Fitzmaurice, Thomas
Oprea, Corina
Moreau, Philippe
LEUKEMIA, 2023, 37 (07) : 1521 - 1529
[18] Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Enrique M. Ocio
Aurore Perrot
Pierre Bories
Jesus F. San-Miguel
Igor W. Blau
Lionel Karlin
Joaquin Martinez-Lopez
Song-Yau Wang
Sara Bringhen
Magda Marcatti
María-Victoria Mateos
Paula Rodriguez-Otero
Stefania Oliva
Axel Nogai
Nadia Le Roux
Liyan Dong
Sandrine Macé
Matthieu Gassiot
Thomas Fitzmaurice
Corina Oprea
Philippe Moreau
Leukemia, 2023, 37 : 1521 - 1529
[19] Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study
Askeland, Frida Bugge Bugge
Haukas, Einar
Slordahl, Tobias S. S.
Klostergaard, Anja
Alexandersen, Tatjana
Lysen, Anna
Abdollahi, Pegah
Hermansen, Emil
Schjesvold, Fredrik
BLOOD, 2024, 144 : 4730 - 4731
[20] Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study
Askeland, Frida Bugge Bugge
Haukas, Einar
Slordahl, Tobias S.
Schjoll, Diana
Lysen, Anna
Hermansen, Emil
Schjesvold, Fredrik
BLOOD, 2022, 140 : 12623 - 12625

← 1 2 3 4 5 →